Image Credit: © nespix – stock.adobe.com
Medidata and Aixial Group have announced a new partnership to streamline clinical trial execution and achieve database lock faster. Per the agreement, Aixial Group will migrate clinical data from one of its business units onto Medidata’s trial management solution, Medidata Platform, creating a Single Source of Truth (SSOT). This will enable study teams to streamline operations and better support patient data privacy.1
“This engagement enables Aixial Group to provide increased consistency and control within their operations, helping them further excel in the global clinical research market,” Janet Butler, executive vice president, head of global sales, Medidata, said in a press release. “Medidata Rave EDC will enhance their support for studies of any size, length, or complexity and translate their productivity into more patients accessing better treatments sooner.”
According to Medidata, the Medidata Platform allows customers to manage their trials in one place. The solution connects multiple stakeholders including patients, sites, and sponsors in a cloud-based environment.
Jonas Möller, managing director, Aixial Group said, “Aixial Group offers our trial sponsors the reliability and flexibility at scale they need to accelerate their clinical research programs and deliver results fast.”
Tim Corbett-Clark, chief technology officer, Aixial Group added, “Consolidating clinical data onto the Medidata Platform will power the experience and expertise of our teams to deliver this superior service for our customers.”
Earlier in July, Medidata announced Eisai as one of its first customers to use the artificial intelligence (AI)-driven Medidata Clinical Data Studio which is powered by the Medidata Platform.2
In a press release from the time, Butler said, “Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data. By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”
Along with other non-Medidata sources, data from the Medidata Platform and Clinical Data Studio are integrated to streamline the import process and enable automatic validation through configured data transfer agreements. With AI, the speed of data review is greatly increased while still maintaining a comprehensive overview of patient data.
“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” Shobha Dhadda, PhD, chief clinical science & operations officer, Eisai, added. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”
References
1. Aixial Group Migrates Specific Clinical Data Portfolio Onto Medidata Platform to Create a Single Source of Truth and Accelerate Database Lock. News release. Medidata. September 3, 2024. Accessed September 4, 2024. https://www.businesswire.com/news/home/20240903518594/en/Aixial-Group-Migrates-Specific-Clinical-Data-Portfolio-Onto-Medidata-Platform-to-Create-a-Single-Source-of-Truth-and-Accelerate-Database-Lock
2. Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience. News release. Medidata. July 26, 2024. Accessed September 4, 2024. https://www.businesswire.com/news/home/20240724837236/en/Eisai-Selects-Medidata%E2%80%99s-Clinical-Data-Studio-to-Enhance-and-Modernize-Clinical-Trial-Efficiency-and-Patient-Experience